Loading patent…
OwnerAlain P. ROLLAND, John Doukas +1inventors
InventorsAlain P. ROLLAND, John Doukas, Dmitri Kharkevitch
Estimating the term…
The present disclosure provides combinations of immunotherapeutics and methods for treating medical conditions that are characterized by the lack of an effective immune response, for example as would result following a down-regulation of MHC class I, such as in cancer. The immunotherapeutic compositions of the invention, which can be used to treat the medical conditions, include one or more immunostimulatory antibodies or molecules having specificity for CTLA-4, PD-1, PD-L1, PD-L2, CD40, OX40, CD137, GITR, ILT2, or ILT3, or ligands for these molecules (e.g., an isolated fully-human monoclonal antibody) in association with one or more alloantigens, such as, vector(s) capable of expressing protein(s) or peptide(s) that stimulate T-cell immunity against tissues or cells, formulated in a pharmaceutically acceptable carrier. The proteins or peptides may comprise class I major histocompatibility complex (MHC) antigens, β2-microglobulins, or cytokines. The MHC antigen may be foreign to the subject. The MHC antigen may be HLA-B7.
An immunotherapeutic composition comprising (a) one or more binding component(s), in association with (b) one or more immunostimulatory therapeutic nucleic acid molecule(s) and, optionally, a pharmaceutically acceptable carrier.
A kit comprising a first container comprising a controlled release formulation of an antibody selected from the group consisting of ipilimumab, BMS-936558, BMS-936559, BMS-663513, CT-011, MK-3475, MPDL3280A, CP-870,893, TRX518, or TRX385, said formulation comprising an amount of antibody effective to treat or reduce and/or prevent melanoma, and a second container comprising an immunostimulatory therapeutic nucleic acid molecule and a pharmaceutically acceptable carrier.
Dependencies are inferred from the claim text.